Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease.
It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
| Country | United States | 
| Founded | 1996 | 
| Industry | Biotechnology | 
| Sector | Healthcare | 
| Employees | 8 | 
| CEO | J. Finley | 
Contact Details
| Address: 7750 El Camino Real, Suite 2A Carlsbad, California 92009 United States | |
| Phone | 858 704 4900 | 
| Website | palisadebio.com | 
Stock Details
| Ticker Symbol | PALI | 
| Exchange | NASDAQ | 
| Fiscal Year | January - December | 
| Reporting Currency | USD | 
| CIK Code | 0001357459 | 
| CUSIP Number | 696389105 | 
| ISIN Number | US6963894026 | 
| Employer ID | 52-2007292 | 
| SIC Code | 2836 | 
Key Executives
| Name | Position | 
|---|---|
| J. D. Finley | Chief Executive Officer, Chief Financial Officer and Director | 
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | Chief Operating Officer and Chief Medical Officer | 
| Dr. Joerg Heyer Ph.D. | Head of Translational Science and Medicine | 
| Ryker Willie | Senior Vice President of Finance and Corporate Controller | 
Latest SEC Filings
| Date | Type | Title | 
|---|---|---|
| Oct 28, 2025 | DEF 14A | Other definitive proxy statements | 
| Oct 22, 2025 | 8-K | Current Report | 
| Oct 20, 2025 | 8-K | Current Report | 
| Oct 17, 2025 | PRE 14A | Other preliminary proxy statements | 
| Oct 16, 2025 | 8-K | Current Report | 
| Oct 9, 2025 | 8-K | Current Report | 
| Oct 9, 2025 | SCHEDULE 13G | Filing | 
| Oct 9, 2025 | SCHEDULE 13G | Filing | 
| Oct 8, 2025 | SCHEDULE 13G | Filing | 
| Oct 8, 2025 | SCHEDULE 13G | Filing |